Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1

Ira M. Jacobson, Robert S. Brown, Jonathan McCone, Martin Black, Clive Albert, Michael S. Dragutsky, Firdous A. Siddiqui, Thomas Hargrave, Paul Y. Kwo, Louis Lambiase, Greg W. Galler, Victor Araya, Bradley Freilich, Joann Harvey, Louis H. Griffel, Clifford A. Brass

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

WIN-R (Weight-based dosing of pegINterferon alfa-2b and Ribavirin) was a multicenter, randomized, open-label, investigator-initiated trial involving 236 community and academic sites in the United States, comparing response to pegylated interferon (PEG-IFN) alfa-2b plus a flat or weight-based dose of ribavirin (RBV) in treatment-naive patients with chronic hepatitis C and compensated liver disease. Patients were randomized to receive PEG-IFN alfa-2b at 1.5 μg/kg/week plus flat-dose (800 mg/day) or weight-based-dose RBV (800 mg/day for weight <65 kg, 1000 mg/day for 65-85 kg, 1200 mg/day for >85-105 kg, or 1400 mg/day for > 05-<125 kg). Sustained virologic response (SVR; undetectable [<125 IU/mL] hepatitis C virus [HCV] RNA at end of follow-up) in patients ≥65 kg was the primary end point. Low SVR rates have been reported among African American individuals, in whom there is a preponderance of HCV genotype 1. This subanarysis of WIN-R was conducted to evaluate the efficacy of weight-based dosing among African American individuals with genotype 1 infection enrolled in the trial. Of 362 African American patients in the primary efficacy analysis, 188 received RBV flat dosing and 174 received weight-based dosing. SVR rates were higher (21% versus 10%; P = 0.0006) and relapse rates were lower (22% versus 30%) in the weight-based-dose group than in the flat-dose group. Safety and rates of drug discontinuation were similar between the 2 groups. Conclusion: Weight-based dosing of RBV is more effective than flat dosing in combination with PEG-IFN alfa-2b in African American individuals with HCV genotype 1. Even with weight-based dosing, response rates in African American individuals are lower than reported in other ethnic groups.

Original languageEnglish (US)
Pages (from-to)982-990
Number of pages9
JournalHepatology
Volume46
Issue number4
DOIs
StatePublished - Oct 1 2007
Externally publishedYes

Fingerprint

Ribavirin
Hepacivirus
African Americans
Genotype
Weights and Measures
peginterferon alfa-2b
Chronic Hepatitis C
Ethnic Groups
Liver Diseases
Research Personnel
RNA
Safety
Recurrence

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

Jacobson, I. M., Brown, R. S., McCone, J., Black, M., Albert, C., Dragutsky, M. S., ... Brass, C. A. (2007). Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology, 46(4), 982-990. https://doi.org/10.1002/hep.21670

Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. / Jacobson, Ira M.; Brown, Robert S.; McCone, Jonathan; Black, Martin; Albert, Clive; Dragutsky, Michael S.; Siddiqui, Firdous A.; Hargrave, Thomas; Kwo, Paul Y.; Lambiase, Louis; Galler, Greg W.; Araya, Victor; Freilich, Bradley; Harvey, Joann; Griffel, Louis H.; Brass, Clifford A.

In: Hepatology, Vol. 46, No. 4, 01.10.2007, p. 982-990.

Research output: Contribution to journalArticle

Jacobson, IM, Brown, RS, McCone, J, Black, M, Albert, C, Dragutsky, MS, Siddiqui, FA, Hargrave, T, Kwo, PY, Lambiase, L, Galler, GW, Araya, V, Freilich, B, Harvey, J, Griffel, LH & Brass, CA 2007, 'Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1', Hepatology, vol. 46, no. 4, pp. 982-990. https://doi.org/10.1002/hep.21670
Jacobson, Ira M. ; Brown, Robert S. ; McCone, Jonathan ; Black, Martin ; Albert, Clive ; Dragutsky, Michael S. ; Siddiqui, Firdous A. ; Hargrave, Thomas ; Kwo, Paul Y. ; Lambiase, Louis ; Galler, Greg W. ; Araya, Victor ; Freilich, Bradley ; Harvey, Joann ; Griffel, Louis H. ; Brass, Clifford A. / Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. In: Hepatology. 2007 ; Vol. 46, No. 4. pp. 982-990.
@article{bdcdfddf459743e9a7256c0dc489842a,
title = "Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1",
abstract = "WIN-R (Weight-based dosing of pegINterferon alfa-2b and Ribavirin) was a multicenter, randomized, open-label, investigator-initiated trial involving 236 community and academic sites in the United States, comparing response to pegylated interferon (PEG-IFN) alfa-2b plus a flat or weight-based dose of ribavirin (RBV) in treatment-naive patients with chronic hepatitis C and compensated liver disease. Patients were randomized to receive PEG-IFN alfa-2b at 1.5 μg/kg/week plus flat-dose (800 mg/day) or weight-based-dose RBV (800 mg/day for weight <65 kg, 1000 mg/day for 65-85 kg, 1200 mg/day for >85-105 kg, or 1400 mg/day for > 05-<125 kg). Sustained virologic response (SVR; undetectable [<125 IU/mL] hepatitis C virus [HCV] RNA at end of follow-up) in patients ≥65 kg was the primary end point. Low SVR rates have been reported among African American individuals, in whom there is a preponderance of HCV genotype 1. This subanarysis of WIN-R was conducted to evaluate the efficacy of weight-based dosing among African American individuals with genotype 1 infection enrolled in the trial. Of 362 African American patients in the primary efficacy analysis, 188 received RBV flat dosing and 174 received weight-based dosing. SVR rates were higher (21{\%} versus 10{\%}; P = 0.0006) and relapse rates were lower (22{\%} versus 30{\%}) in the weight-based-dose group than in the flat-dose group. Safety and rates of drug discontinuation were similar between the 2 groups. Conclusion: Weight-based dosing of RBV is more effective than flat dosing in combination with PEG-IFN alfa-2b in African American individuals with HCV genotype 1. Even with weight-based dosing, response rates in African American individuals are lower than reported in other ethnic groups.",
author = "Jacobson, {Ira M.} and Brown, {Robert S.} and Jonathan McCone and Martin Black and Clive Albert and Dragutsky, {Michael S.} and Siddiqui, {Firdous A.} and Thomas Hargrave and Kwo, {Paul Y.} and Louis Lambiase and Galler, {Greg W.} and Victor Araya and Bradley Freilich and Joann Harvey and Griffel, {Louis H.} and Brass, {Clifford A.}",
year = "2007",
month = "10",
day = "1",
doi = "10.1002/hep.21670",
language = "English (US)",
volume = "46",
pages = "982--990",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1

AU - Jacobson, Ira M.

AU - Brown, Robert S.

AU - McCone, Jonathan

AU - Black, Martin

AU - Albert, Clive

AU - Dragutsky, Michael S.

AU - Siddiqui, Firdous A.

AU - Hargrave, Thomas

AU - Kwo, Paul Y.

AU - Lambiase, Louis

AU - Galler, Greg W.

AU - Araya, Victor

AU - Freilich, Bradley

AU - Harvey, Joann

AU - Griffel, Louis H.

AU - Brass, Clifford A.

PY - 2007/10/1

Y1 - 2007/10/1

N2 - WIN-R (Weight-based dosing of pegINterferon alfa-2b and Ribavirin) was a multicenter, randomized, open-label, investigator-initiated trial involving 236 community and academic sites in the United States, comparing response to pegylated interferon (PEG-IFN) alfa-2b plus a flat or weight-based dose of ribavirin (RBV) in treatment-naive patients with chronic hepatitis C and compensated liver disease. Patients were randomized to receive PEG-IFN alfa-2b at 1.5 μg/kg/week plus flat-dose (800 mg/day) or weight-based-dose RBV (800 mg/day for weight <65 kg, 1000 mg/day for 65-85 kg, 1200 mg/day for >85-105 kg, or 1400 mg/day for > 05-<125 kg). Sustained virologic response (SVR; undetectable [<125 IU/mL] hepatitis C virus [HCV] RNA at end of follow-up) in patients ≥65 kg was the primary end point. Low SVR rates have been reported among African American individuals, in whom there is a preponderance of HCV genotype 1. This subanarysis of WIN-R was conducted to evaluate the efficacy of weight-based dosing among African American individuals with genotype 1 infection enrolled in the trial. Of 362 African American patients in the primary efficacy analysis, 188 received RBV flat dosing and 174 received weight-based dosing. SVR rates were higher (21% versus 10%; P = 0.0006) and relapse rates were lower (22% versus 30%) in the weight-based-dose group than in the flat-dose group. Safety and rates of drug discontinuation were similar between the 2 groups. Conclusion: Weight-based dosing of RBV is more effective than flat dosing in combination with PEG-IFN alfa-2b in African American individuals with HCV genotype 1. Even with weight-based dosing, response rates in African American individuals are lower than reported in other ethnic groups.

AB - WIN-R (Weight-based dosing of pegINterferon alfa-2b and Ribavirin) was a multicenter, randomized, open-label, investigator-initiated trial involving 236 community and academic sites in the United States, comparing response to pegylated interferon (PEG-IFN) alfa-2b plus a flat or weight-based dose of ribavirin (RBV) in treatment-naive patients with chronic hepatitis C and compensated liver disease. Patients were randomized to receive PEG-IFN alfa-2b at 1.5 μg/kg/week plus flat-dose (800 mg/day) or weight-based-dose RBV (800 mg/day for weight <65 kg, 1000 mg/day for 65-85 kg, 1200 mg/day for >85-105 kg, or 1400 mg/day for > 05-<125 kg). Sustained virologic response (SVR; undetectable [<125 IU/mL] hepatitis C virus [HCV] RNA at end of follow-up) in patients ≥65 kg was the primary end point. Low SVR rates have been reported among African American individuals, in whom there is a preponderance of HCV genotype 1. This subanarysis of WIN-R was conducted to evaluate the efficacy of weight-based dosing among African American individuals with genotype 1 infection enrolled in the trial. Of 362 African American patients in the primary efficacy analysis, 188 received RBV flat dosing and 174 received weight-based dosing. SVR rates were higher (21% versus 10%; P = 0.0006) and relapse rates were lower (22% versus 30%) in the weight-based-dose group than in the flat-dose group. Safety and rates of drug discontinuation were similar between the 2 groups. Conclusion: Weight-based dosing of RBV is more effective than flat dosing in combination with PEG-IFN alfa-2b in African American individuals with HCV genotype 1. Even with weight-based dosing, response rates in African American individuals are lower than reported in other ethnic groups.

UR - http://www.scopus.com/inward/record.url?scp=36349022057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36349022057&partnerID=8YFLogxK

U2 - 10.1002/hep.21670

DO - 10.1002/hep.21670

M3 - Article

VL - 46

SP - 982

EP - 990

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 4

ER -